Department of Medical Specialties and Public Health, University Rey Juan Carlos, Alcorcón, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Nursing Research Group (Nursing Department), Madrid, Spain.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2334001. doi: 10.1080/21645515.2024.2334001. Epub 2024 Apr 1.
In 2020, there were approximately 50,865 anal cancer cases and 36,068 penile cancer cases worldwide. HPV is considered the main causal agent for the development of anal cancer and one of the causal agents responsible for the development of penile cancer. The aim of this epidemiological, descriptive, retrospective study was to describe the burden of hospitalization associated with anal neoplasms in men and women and with penis neoplasms in men in Spain from 2016 to 2020. The National Hospital Data Surveillance System of the Ministry of Health, Conjunto Mínimo Básico de Datos, provided the discharge information used in this observational retrospective analysis. A total of 3,542 hospitalizations due to anal cancer and 4,270 hospitalizations due to penile cancer were found; For anal cancer, 57.4% of the hospitalizations occurred in men, and these hospitalizations were also associated with significantly younger mean age, longer hospital stays and greater costs than those in women. HIV was diagnosed in 11.19% of the patients with anal cancer and 1.74% of the patients with penile cancer. The hospitalization rate was 2.07 for men and 1.45 for women per 100,000 in anal cancer and of 4.38 per 100,000 men in penile cancer. The mortality rate was 0.21 for men and 0.12 for women per 100,000 in anal cancer and 0.31 per 100.000 men in penile cancer and the case-fatality rate was 10.07% in men and 8,26% in women for anal cancer and 7.04% in penile cancer. HIV diagnosis significantly increased the cost of hospitalization. For all the studied diagnoses, the median length of hospital stays and hospitalization cost increased with age. Our study offers relevant data on the burden of hospitalization for anal and penile cancer in Spain. This information can be useful for future assessment on the impact of preventive measures, such as screening or vaccination in Spain.
2020 年,全球约有 50865 例肛门癌病例和 36068 例阴茎癌病例。HPV 被认为是肛门癌发展的主要致病因素,也是导致阴茎癌发展的致病因素之一。本项流行病学、描述性、回顾性研究旨在描述 2016 年至 2020 年期间西班牙男性和女性肛门肿瘤以及男性阴茎肿瘤住院的负担。该研究数据来源于卫生部国家医院数据监测系统的最低基本数据集。研究共发现 3542 例肛门癌住院和 4270 例阴茎癌住院病例;肛门癌患者中,57.4%为男性,与女性相比,这些患者的平均年龄更轻,住院时间更长,费用更高。11.19%的肛门癌患者和 1.74%的阴茎癌患者被诊断为 HIV。肛门癌的住院率为每 10 万人中有 2.07 例男性和 1.45 例女性,阴茎癌的住院率为每 10 万人中有 4.38 例男性。肛门癌的死亡率为每 10 万人中有 0.21 例男性和 0.12 例女性,阴茎癌的死亡率为每 10 万人中有 0.31 例男性,肛门癌的病死率为 10.07%男性和 8.26%女性,阴茎癌的病死率为 7.04%。HIV 诊断显著增加了住院费用。对于所有研究诊断,住院时间和住院费用的中位数均随年龄增长而增加。本研究提供了西班牙肛门癌和阴茎癌住院负担的相关数据。这些信息对于未来评估西班牙筛查或疫苗接种等预防措施的影响可能有用。